61results about How to "Meet the needs of clinical treatment" patented technology

The invention discloses a transdermal patch containing pramipexole. The transdermal patch comprises a medicine carrying pressure-sensitive adhesive layer, the pramipexole, solvent and penetration enhancer, wherein the medicine carrying pressure-sensitive adhesive layer comprises acrylate pressure-sensitive adhesive containing carboxyl base groups and acrylate pressure-sensitive adhesive containing hydroxyl base groups, which form mixed pressure-sensitive adhesive; the pramipexole is dissolved in the acrylate mixed pressure-sensitive adhesive, with the content being 10 to 30 weight percent; the content of the mixed pressure-sensitive adhesive is 50 to 80 weight percent; the content of the solvent is 5 to 20 weight percent; the content of the penetration enhancer is 2 to 15 weight percent. The pramipexole can be dissolved in a mixed pressure-sensitive adhesive patch in a high concentration way and is not crystallized, the medicine availability is high, the pramipexole has good stability in pressure-sensitive adhesive matrix, and can be continuously administrated for 5 to 7 days in a transdermal way at a relatively stable permeation rate of being larger than 5.0 micrograms / cm2 / h, and the application area of a pramipexole patch is smaller than 40cm2.

The invention discloses a risperidone sustained-release gel injection and preparation method thereof. The risperidone sustained-release gel injection is composed of risperidone or analogue thereof, biological degradable polymer and biocompatible dissolvent, wherein the mass ratio between risperidone or analogue thereof and sum of biological degradable polymer and biocompatible dissolvant is 1:3-67. Continuous and constant-speed release of risperidone is up to several weeks immediately after the injection is injected into appropriate part in vivo, thereby improving compliance therapy in psychotic with risperidone analogue.

The invention specifically relates to a pramipexole weekly transdermal patch and a preparation method thereof, belonging to the field of pharmaceutical preparations. The pramipexole weekly transdermal patch comprises three parts: a drug reservoir, an anti-adhesive layer and a backing layer. The invention adopts the hydrophilic substrate mixed penetration enhancer and the lamination pouring method to prepare the double-layer patch, which effectively solves the problem in the preparation of the multi-layer film, and can ensure the constant-speed release of the drug within seven days. Animal experiments show that it is non-irritating and sensitizing to the skin. The patch of the invention has the advantages of clear curative effect, stable quality, good safety and convenient use, and is used for the treatment of Parkinson's disease.

The invention provides a pharmaceutical composition for treating embolism and a preparation method thereof, the pharmaceutical composition comprises a hydroxyl-contained biocompatible polymer material and a monomer containing unsaturated double bonds and anion groups, as well as a polymer generated by polymerization reaction of an optional vinyl monomer, wherein the polymerization is initiated through free radicles, and bleomycin or pingyangmycin is combined on the anion groups of the generated polymer. The preparation method combines the bleomycin or the pingyangmycin on a carrier of the polymer, thereby being capable of fully playing the dual effects of an anti-tumor antibiotic and a hardening agent owned by the bleomycin or the pingyangmycin during the embolism treatment. The anion part of the polymer can be properly combined with the bleomycin or the pingyangmycin which is rich in amino groups, thereby not only realizing the higher drug loading, but also leading the drug in an emboliaztion agent to be exchanged by cation in human body, and further realizing the slow release. In addition, the embolic carrier of the polymer has the advantages of simple prepration technology andlow cost, thereby being applicable to large-scale industrial production.

The invention discloses a concentration gradient rhIL-2 dependent iNKT (invariant natural killer) cell amplification method and an application thereof. The method includes: 1), extracting PBMCs (peripheral blood mononuclear cell); 2), adding alpha-GalCer 100ng / ml in final concentration to the extracted PBMCs in the step 1) for culture for 48 hours; gradually increasing concentration of rhIL-2 in a culture medium in a gradient manner in the cultured cells in the step 2). The iNKT cells are obtained on the 21 day of culture, the number of the iNKT cells is increased by 100,000 times, more than 90% of the cells are CD4-iNKT cells, and functions of immune reaction up-regulation and direct tumor killing are achieved; the method is higher in amplification efficiency in stimulating and amplifying the iNKT cells, Th1 sampled iNKT cells are selectively amplified, and immune enhancement of the in vitro amplified iNKT cells and tumor immune surveillance and killing functions are strengthened.